- Home
- ULY vs BIAF Comparison
ULY vs BIAF Comparison
Compare ULY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULY
- BIAF
- Stock Information
- Founded
- ULY 2013
- BIAF 2014
- Country
- ULY United States
- BIAF United States
- Employees
- ULY N/A
- BIAF N/A
- Industry
- ULY
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ULY
- BIAF Health Care
- Exchange
- ULY Nasdaq
- BIAF Nasdaq
- Market Cap
- ULY 6.3M
- BIAF 7.6M
- IPO Year
- ULY N/A
- BIAF 2022
- Fundamental
- Price
- ULY $3.78
- BIAF $0.17
- Analyst Decision
- ULY Strong Buy
- BIAF Hold
- Analyst Count
- ULY 2
- BIAF 1
- Target Price
- ULY $11.50
- BIAF N/A
- AVG Volume (30 Days)
- ULY 90.4K
- BIAF 12.0M
- Earning Date
- ULY 11-11-2025
- BIAF 11-13-2025
- Dividend Yield
- ULY N/A
- BIAF N/A
- EPS Growth
- ULY N/A
- BIAF N/A
- EPS
- ULY N/A
- BIAF N/A
- Revenue
- ULY $131,235,000.00
- BIAF $7,681,059.00
- Revenue This Year
- ULY N/A
- BIAF N/A
- Revenue Next Year
- ULY $20.23
- BIAF $20.04
- P/E Ratio
- ULY N/A
- BIAF N/A
- Revenue Growth
- ULY N/A
- BIAF 4.99
- 52 Week Low
- ULY $2.99
- BIAF $0.16
- 52 Week High
- ULY $17.99
- BIAF $2.26
- Technical
- Relative Strength Index (RSI)
- ULY 35.41
- BIAF 35.35
- Support Level
- ULY $3.70
- BIAF $0.24
- Resistance Level
- ULY $4.29
- BIAF $0.45
- Average True Range (ATR)
- ULY 0.40
- BIAF 0.03
- MACD
- ULY 0.04
- BIAF -0.00
- Stochastic Oscillator
- ULY 9.80
- BIAF 11.08
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.